The genes encoding the measles virus (MV) haemagglutinin (H) and fusion (F) proteins were placed under the control of the human cytomegalovirus immediate early promoter in a replication-deficient adenovirus vector. Immunofluorescence and radioimmune precipitation demonstrated the synthesis of each protein and biological activity was confirmed by the detection of haemadsorption and fusion activities in infected cells. Oral as well as parenteral administration of the H-expressing recombinant adenovirus elicited a significant protective response in mice challenged with MV. While the F-expressing adenovirus failed to protect mice, cotton rats immunized with either the H-or Fexpressing recombinant showed reduced MV replication in the lungs. Antibodies elicited in mice following immunization with either recombinant had no in vitro neutralizing activity, suggesting a protective mechanism involving a cell-mediated immune response. This study demonstrates the feasibility of using oral administration of adenovirus recombinants to induce protective responses to heterologous proteins.
Measles continues to be a devastating disease of children in developing countries, especially in Africa, not only because of logistical problems, but also because the current live-attenuated vaccine is not effective in inducing immunity in the face of the maternal antibodies present in the children less than 1 year old who need to be vaccinated (WHO, 1993 is an urgent need for a robust vaccine which is efficacious by the oral route and can be given during the first few months of life. An adenovirus vaccine has been administered to United States military recruits since 1969 to successfully control acute respiratory disease (Top et al., 1971 a, b ; Rubin & Rorke, 1994) . This extensive record of safe use has prompted investigations of the use of adenoviruses as vectors in the construction of vaccines against other diseases.
We have previously demonstrated that an adenovirus recombinant expressing the measles virus (MV) N protein is expressed to high levels in mammalian cells, produces authentic ' nucleocapsid-like structures ' and elicits protective immune responses in mice after parenteral administration (Fooks et al., 1995) . We describe here the construction and initial characterization of replication-deficient adenovirus recombinants expressing the MV H and F genes under the control of the human cytomegalovirus (HCMV) immediate early promoter. The recombinants were generated using previously published methods (McGrory et al., 1988) . Co-transfection of 293 cells with pJM17, which contains the adenovirus dl309 genome deleted in the E1 region, together with an inserted stuffer plasmid, pBRX (Bett et al., 1995) , and either pMV88 or pMV95, resulted in homologous recombination to generate the replication-deficient adenovirus recombinants RAd88 and RAd95, containing the MV H and F genes respectively. Each recombinant virus was plaque-purified three times on 293 cells. The presence of the MV H and F genes was confirmed using Southern hybridization, which showed specific bands of the expected sizes (1n7 kb for H and 1n8 kb for F).
Immunofluorescence and radioimmune precipitation with specific monoclonal antibodies demonstrated the synthesis of each protein (results not shown). An important biological activity of the recombinant H protein was tested by examining the ability of cells infected with the adenovirus recombinant RAd88 to mimic the ability of MV-infected cells to adsorb erythrocytes, which is mediated through the expression of H protein on the cell surface ( Fig. 1 a-c These results show that the recombinant F protein expressed from the adenovirus vector is also present on the surface of the infected cell and biologically active.
We determined whether these adenovirus recombinants could elicit immune responses protective against MV challenge in mice and cotton rats, when administered by parenteral or mucosal routes. In a first protection experiment, female 3-week-old C3H\He mice (Harlan-Olac) were immunized with RAd88 or RAd95 in two doses containing 10) p.f.u. 1 week apart. For intraperitoneal (i.p.) immunization the recombinant adenovirus was diluted in 100 µl PBS. For oral immunization the mice were starved of food and water for 6 h before administration of virus (diluted to a final volume of 500 µl with 0n1 M bicarbonate buffer, pH 8n9) by gavage using a stainless steel 22 gauge oral-dosing cannula. Mice were challenged intercranially (i.c.) at 5 weeks of age using 20 µl (10% p.f.u.\ml) of the rodent-adapted MV strain (CAM\RB). After i.p. immunization of mice, the recombinant adenovirus expressing the MV H gene elicited a significant protective response (χ# test ; P 0n001) against i.c. challenge with rodent-adapted MV. This degree of protection was similar to that found with the N recombinant (Fooks et al., 1995) . In contrast, protection elicited by i.p. administration of the MV F-expressing recombinant did not achieve statistical significance (Fig. 2 a) . Oral delivery of recombinant adenoviruses expressing the H protein was also effective in eliciting significant protective responses (χ# test ; P 0n001), albeit at a lower level than immunization via the i.p. route. The recombinant expressing the F protein again gave rise only to a weak protective response which was not statistically significant (Fig. 2 b) .
We also examined the ability of the recombinant adenoviruses to reduce lung MV titres in intranasally infected cotton rats. Cotton rats (inbred strain COTTON\NIco) were obtained from Iffa Credo, France. The 6-to 12-week-old sex-matched animals had been reared under specified pathogen-free conditions and were maintained in a barrier-free system. No more than three animals were housed together under controlled environmental conditions of 22 mC, 55-60 % humidity with a 12 h light cycle. Animals were anaesthetized and immunized twice with a 1 week interval between doses. Animals received one of the adenovirus recombinants at 10) p.f.u. per dose by the i.p. route or 10( p.f.u. per dose intranasally (i.n.). One week later animals were challenged i.n. with 10' p.f.u. of MV CAM strain (day 0). After 8 days, the animals were asphyxiated with CO # , and the lungs removed on day 4 and weighed. Lung tissue was minced with scissors and disrupted in a glass Dounce homogenizer. Serial 10-fold dilutions of virus-containing supernatant were assessed for the presence and levels of infectious virus in a 48-well plate microassay using Vero cells. Plates were scored microscopically for CPE after 7 days. The levels of virus in inocula were expressed as TCID &! , calculated according to the method of Reed & Muench (1938) . Intranasal infection of cotton rats with MV resulted in recoverable viable virus from lung homogenates for 8 days during the acute phase of infection, with peak virus titres on day 4. Histologically, inflammation of lung tissue was evident and virus could also be demonstrated by immunohistology. Mainly leukocytes were infected, because virus isolation was easily performed from lung lavage fluids (Wyde et al., 1992) . Immunization by the i.p. route with adenoviruses expressing the MV H or F protein led to reduced virus titres in the lung (Fig. 3 a) , and histological signs of infection were absent. This reduction in lung MV titres after challenge was highly significant when analysed using pairwise comparisons in a classical Scheffe test (P 0n001). However, i.n. immunization of cotton rats with adenoviruses expressing the H or F proteins did not result in significant levels of protection (P value for this data when analysed using pairwise comparisons l 0n09) (Fig.  3 b) . Neutralizing antibody titres were determined by the method of Albrecht et al. (1981) . Oral and i.p. immunization of C3H\He mice (H-2 k restricted), SWR mice (H-2 q restricted) and BALB\c mice (H-2 d restricted) were performed with both BACJ A. R. Fooks and others A. R. Fooks and others the H-and F-expressing recombinant adenoviruses. Mice vaccinated with either recombinant failed to mount a significant neutralizing antibody response although low levels of MVspecific IgG were detected by ELISA (data not shown).
Reported here are the construction and initial characterization of two replication-deficient adenovirus recombinants expressing the MV H and F proteins under the control of the highly efficient HCMV transcriptional promoter. Both recombinant viruses are genetically stable and capable of growing to high titres in helper cell lines. In accord with previous results (Alkhatib & Briedis, 1988 ; Alkhatib et al., 1990) , cells infected with these recombinants synthesize MV proteins of the expected sizes which are displayed on the cell surface and demonstrate the characteristic biological functions seen in MV-infected cells. In contrast, however, the recombinant adenoviruses previously described (Alkhatib & Briedis, 1988 ; Alkhatib et al., 1990 ) expressed low levels of MV H and F proteins under the control of an adenovirus promoter ; there were no in vivo data reported and their protective efficacy was not investigated. Both recombinant adenoviruses which we report in this study differ significantly from those described previously. In the experiments described here, neither oral nor parenteral immunization of mice with the H-or the F-expressing adenovirus recombinants resulted in any detectable virus-neutralizing antibodies. In contrast, such antibodies, specific for both H and F proteins, are found as a result of human measles infection and have been found in animals immunized with vaccinia viruses containing these genes (Brinkmann et al., 1991 ; Drillien et al., 1988) . However, poxvirus vectors expressing the related rinderpest virus haemagglutinin and fusion glycoproteins elicited poor and variable neutralizing antibody responses, although they protected both rabbits and cattle following a lethal virus challenge (Barrett et al., 1989 ; . Similarly, immunization with a capripox vector containing the F gene of peste des petits ruminants virus did not elicit neutralizing antibodies (Romero et al., 1994 b) . The protective efficacy of these viruses was tested in two experimental animal models, using parenteral and mucosal routes of administration in each case. Mice immunized i.p. with RAd88 expressing MV H were protected against i.c. challenge, as we have shown using recombinant adenoviruses containing the MV N gene. Following the lethal challenge, virus isolation was not attempted since previous work has shown that MV could not be recovered from the brains of surviving animals (Fooks et al., 1995) . The absence of neutralizing antibodies suggests that the mechanism of the observed protective effect is likely to be cell-mediated rather than humoral. In the cotton rat model, i.p. vaccination with either RAd88 and RAd95 also resulted in a significant reduction in MV titres in the lung. Previously, vaccinia virusvectored systems expressing MV N, H or F genes have been shown to be capable of stimulating both humoral and cellmediated immune responses and conferring protection against lethal challenge (Drillien et al., 1988 ; Wild et al., 1992) . Our data on protection with adenovirus-vectored expression of MV H and N proteins are consistent with this picture, while our F-expressing recombinant appears to be significantly effective only after parenteral administration in the cotton rat. Cotton rats, which were used as described previously (Niewiesk et al., 1997) , are an attractive alternative rodent model for MV vaccine assessment, since they are susceptible to infection by nasal routes, thereby mimicking a natural MV infection more closely. Oral delivery offers a non-invasive and rapid route of immunization, especially suitable for children in their first year of life, which may be especially useful to combat viruses such as MV which gain entry via the upper respiratory tract and possibly other mucosal surfaces. Oral vaccines can access the gut-associated lymphoid tissue (GALT), providing the opportunity to protect mucosal surfaces of the gut and elsewhere, as well as a systemic immune response. It has previously been shown that oral administration of replicationcompetent adenovirus recombinants can elicit both humoral and cellular responses to a transgene product (Lubeck et al., 1989 ; Flanagan et al., 1997) . However, a replication-deficient adenovirus recombinant expressing rabies virus glycoprotein did not induce an immune response when delivered orally, although it was strikingly effective after inoculation parenterally or by way of airway epithelium (Xiang et al., 1996) . In contrast, our results show that oral immunization of mice with replication-deficient adenovirus recombinants can be effective in eliciting significant levels of protection against MV challenge. This is an encouraging result, as it shows for the first time that oral vaccination against MV is possible. It is likely that improvements in techniques and delivery systems will increase the levels of protection achieved by the oral route. 
